Core Viewpoint - GSK is undergoing a leadership change with the appointment of Luke Miels as the new CEO, effective January 1, 2026, amidst challenges in its core vaccine business and a goal to exceed £40 billion in total sales by 2031 [1][15]. Group 1: Leadership Transition - GSK announced the appointment of Luke Miels as CEO candidate, succeeding Emma Walmsley, who has led the company since September 2016 [1][2]. - Under Walmsley's leadership, GSK focused on biopharmaceuticals, successfully splitting its consumer healthcare business and prioritizing specialty medicines and vaccines [2][3]. Group 2: Financial Performance - GSK's total revenue for 2024 is projected to grow by only 3% to £31.376 billion, falling out of the top ten global pharmaceutical companies due to a decline in its core vaccine business [1][4]. - In 2023, GSK reported total revenue of £30.328 billion, a 5% increase year-over-year, with the vaccine segment growing by 25% [4][10]. Group 3: Business Segments - The specialty medicines segment showed strong growth, contributing £11.81 billion in 2024, with a year-over-year increase of 19% [7][13]. - The vaccine segment faced challenges, with revenues declining by 4% in 2024, while the oral and respiratory segments showed mixed results [10][11]. Group 4: Strategic Focus - GSK aims to find new growth drivers, particularly in oncology and respiratory/inflammation areas, where Miels has previously contributed significantly [15][16]. - Recent acquisitions and partnerships, including a $2 billion acquisition of Boston Pharmaceuticals, indicate GSK's strategy to enhance its pipeline and product offerings [16][21]. Group 5: Future Outlook - GSK's success in achieving its £40 billion sales target by 2031 will depend on the successful execution of its innovative pipeline and addressing challenges in its vaccine and HIV segments [22].